Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Selzentry HIV Drug Faces India Opposition As Too Expensive (India)

This article was originally published in PharmAsia News

Executive Summary

Patient groups and two organizations are challenging the patent India gave to Pfizer for its Selzentry (maraviroc), one of a new class of oral AIDS drugs intended as second-line treatments. Medicines Sans frontiers and a Mumbai lawyer group are poring over the patent grant to see if it was justified, with an eye to questions raised about the drug by Europe's patent office. Challengers have a year from last June to mount an official challenge to granting a patent right. The U.S. FDA approved the drug in August. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts